Shire's Vyvanse reports positive adult results

* Drug shows improvement of adult hyperactivity symptoms

* New drug Intuniv significant oppositional syndrome result

LONDON May 18 (Reuters) - Hyperactivity specialist Shire (SHP.L) said emerging lead drug Vyvanse had produced good results in adult tests.

In data released at the American Psychiatric Association meeting, the British company also said on Monday its Intuniv extended release drug showed "significant" improvement in attention deficit hyperactivity disorder (ADHD) symptoms in patients with so-called oppositional syndrome.

On January 26, Shire filed a resubmission to the U.S. Food and Drug Administration (FDA) requesting Intuniv be approved for ADHD in children and adolescents, and results were due in July.

For the Vyvanse tests, the company said adult patients reported improvements in ADHD symptoms, greater satisfaction than with prior prescription medication, dosage convenience, and good tolerability.

Shire, Britain's third largest drugmaker, is pinning its hopes on Vyvanse, along with its new human genetic therapies division, to replace revenue from its former blockbuster Adderall XR, which is facing generic competition.

Vyvanse first went on sale in the United States in July 2007 for the treatment of ADHD in children aged 6-12. It was approved in April 2008 to treat the condition in adults as well, opening up a potentially lucrative new market.

In March this year, Shire struck a deal with GlaxoSmithKline (GSK.L) to co-promote Vyvanse in the United States, sending its shares sharply higher. (Reporting by Ben Deighton, editing by Dan Lalor)